Loading…
Nuvectis Pharma, Inc. is projected to rise to $31.99 by 2027, a +74% move from its current price of $18.35. NVCT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $17.33 | $18.37 | $19.46 | +0.08% |
| Jul 14 | $16.93 | $18.38 | $19.95 | +0.17% |
| Jul 15 | $16.64 | $18.40 | $20.34 | +0.25% |
| Jul 16 | $16.39 | $18.41 | $20.68 | +0.34% |
| Jul 17 | $16.18 | $18.43 | $20.98 | +0.42% |
| Jul 18 | $16.00 | $18.44 | $21.26 | +0.51% |
| Jul 19 | $15.83 | $18.46 | $21.53 | +0.59% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.83 | $18.46 | $21.53 | +0.59% |
| Week 2 | $14.94 | $18.57 | $23.08 | +1.19% |
| Week 3 | $14.31 | $18.68 | $24.38 | +1.79% |
| Week 4 | $13.82 | $18.79 | $25.55 | +2.39% |
| Week 5 | $13.40 | $18.90 | $26.65 | +2.99% |
| Week 6 | $13.05 | $19.01 | $27.70 | +3.60% |
| Week 7 | $12.73 | $19.12 | $28.72 | +4.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focusing on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
NVCT operates in the Healthcare sector and trades as NVCT. The current price is $18.39 with a market cap of $487.8M, and it holds a rank of 3068. The forecast suggests a mixed near-term picture with a neutral 2026 average price of $18.39 and a bullish longer-term trajectory, with higher averages expected from 2027 onward.
A major floor 59.2% below — a decisive break under it would weaken the trend.
The nearest floor, 49.3% below — buyers have tended to step in here.
The nearest ceiling, 55.5% above — a clean break opens room to run.
A major ceiling 106.8% above — clearing it would confirm fresh momentum.
Key NVCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NVCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.98 | Sell | $19.07 | Sell |
| MA 10 | $20.81 | Sell | $19.37 | Sell |
| MA 20 | $18.26 | Buy | $18.10 | Buy |
| MA 50 | $13.38 | Buy | $14.69 | Buy |
| MA 100 | $10.94 | Buy | $12.18 | Buy |
| MA 200 | $9.02 | Buy | $10.25 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.84 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 1.40 | Neutral |
| Williams %R (14) | -84.83 | Info |
| MACD (12,26,9) | -0.54 | Sell |
| ROC (12) | 4.56 | Buy |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 15.17 | Buy |
| TRIX (15) | 2.80 | Buy |
| Awesome (5,34) | 4.16 | Buy |
| Ultimate (7,14,28) | 53.61 | Neutral |
| Momentum (10) | -9.52 | Sell |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 18.20 | Buy |
| ADX (14) | 29.06 | Buy |
| ATR (14) | 1.27 | Info |
The 30-day technical picture is bullish. The RSI(14) is 60. The stock trades around the 50-day simple moving average of $11.92 and above the 200-day simple moving average of $8.57, indicating an upward tilt. Near-term support is $9.31 and resistance is $28.53. The 30-day price range spans from $11.59 to $29.17.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.48 | $18.35 | $30.22 | 0% | Neutral | |
| $23.21 | $31.99 | $47.67 | +74% | Bullish | |
| $25.56 | $37.43 | $59.44 | +104% | Bullish | |
| $28.60 | $44.12 | $73.56 | +140% | Bullish | |
| $25.72 | $41.60 | $72.19 | +127% | Bullish | |
| $27.89 | $47.15 | $84.70 | +157% | Bullish | |
| $31.94 | $56.33 | $104.33 | +207% | Bullish | |
| $33.59 | $61.69 | $117.44 | +236% | Bullish | |
| $48.79 | $93.20 | $181.93 | +408% | Bullish | |
| $54.21 | $107.64 | $215.01 | +487% | Bullish | |
| $74.60 | $165.78 | $363.93 | +803% | Bullish | |
| $143.73 | $319.41 | $734.64 | +16.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.48 | $18.35 | $23.29 | +0.00% |
| August 2026 | $16.80 | $20.35 | $25.67 | +10.89% |
| September 2026 | $16.13 | $19.82 | $25.52 | -2.62% |
| October 2026 | $15.58 | $19.38 | $25.39 | -2.22% |
| November 2026 | $16.79 | $21.10 | $28.05 | +8.88% |
| December 2026 | $17.68 | $22.44 | $30.22 | +6.34% |
Click any year to see its month-by-month NVCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The NVCT price prediction for 2026 points to an average of $18.35 (low $7.48, high $30.22) — a potential gain of 0% on today's $18.35. Price action looks broadly range-bound.
In 2027, NVCT is projected to trade between $23.21 and $47.67, averaging $31.99 — a potential gain of +74% from today's $18.35. That is up +74% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Nuvectis Pharma, Inc.'s 2028 outlook centres on $37.43, within a $25.56 to $59.44 range. That is up +17% on the projected 2027 average. That marks a +104% change versus current levels. Momentum favours further upside here.
By 2029, NVCT could reach as high as $73.56, with a base case around $44.12 and support toward $28.60 — roughly +140% from $18.35. Buyers look set to stay in control over this stretch.
Expect NVCT to range from $25.72 to $72.19 through 2030. The $41.60 average target implies a +127% move from current prices. That is -6% versus the projected 2029 average. Momentum favours further upside here.
The NVCT price prediction for 2031 points to an average of $47.15 (low $27.89, high $84.70) — a potential gain of +157% on today's $18.35. Buyers look set to stay in control over this stretch.
In 2032, NVCT is projected to trade between $31.94 and $104.33, averaging $56.33 — a potential gain of +207% from today's $18.35. That is up +19% on the projected 2031 average. Momentum favours further upside here.
Nuvectis Pharma, Inc.'s 2033 outlook centres on $61.69, within a $33.59 to $117.44 range. That is up +10% on the projected 2032 average. That marks a +236% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, NVCT could reach as high as $181.93, with a base case around $93.20 and support toward $48.79 — roughly +408% from $18.35. Momentum favours further upside here.
Expect NVCT to range from $54.21 to $215.01 through 2035. The $107.64 average target implies a +487% move from current prices. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The NVCT price prediction for 2040 points to an average of $165.78 (low $74.60, high $363.93) — a potential gain of +803% on today's $18.35. Momentum favours further upside here.
In 2050, NVCT is projected to trade between $143.73 and $734.64, averaging $319.41 — a potential gain of +16.4x from today's $18.35. That is up +93% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NVCT today (≈ 54.495913 NVCT) could be worth
$17,406.42
+$16,406.42 (+1641%) by 2050 · US Dollar
Based on the average projected NVCT price of $319.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NVCTwould be worth at today's price.
$1,000 invested in NVCT on Jul 10, 2025 (≈ 122.100128 NVCT) would be worth
$2,240.54
+$1,240.54 (+124.1%) today · 2.24× · US Dollar
Based on a NVCT entry price of $8.19 vs. today's $18.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.57 | $937.66 | -6.2% |
| 1 month ago | $10.31 | $1,779.83 | +78.0% |
| 3 months ago | $8.22 | $2,232.36 | +123.2% |
| 6 months ago | $8.2 | $2,237.8 | +123.8% |
| 1 year ago | $8.19 | $2,240.54 | +124.1% |
| All time (4.4y) ago | $3.25 | $5,646.15 | +464.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NVCT forecast.
Our base-case forecast reaches $37.00 around 2028.
Implied market cap at $37.00: $1.17B
The multi-year forecast shows a bullish bias beyond 2026. In 2030 the average price is projected at $40.83 with an ROI of 122% and bullish sentiment. The forecast also shows 2040 at an average of $161.87 with an ROI of 780.2% and 2050 at an average of $293.30 with an ROI of 1494.9%.
These are estimates and not guarantees, reflecting an expected upward trajectory over time. The 2026 snapshot indicates a neutral outlook with an average of $18.39, before a sustained rise in subsequent years.
Tap a question to reveal the answer.
Avg price $40.83; min $25.21; max $70.93; ROI 122%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages (2027 avg $32.12, 2028 avg $37.26, 2029 avg $42.32, 2030 avg $40.83, 2031 avg $46.52, 2032 avg $53.50, 2033 avg $60.80, 2034 avg $92.05, 2035 avg $102.04, 2040 avg $161.87, 2050 avg $293.30). The 2026 outlook is neutral.
Yes, the forecast max in 2033 is $115.85.
Current price $18.39; market cap $487.8M.
30-day range low $11.59; high $29.17.
Nuvectis Pharma, Inc. Community Discussion
0Share your Nuvectis Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.